Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
N Engl J Med
    June 2024
  1. CHIN NA, Erickson CM
    Alzheimer's Disease, Biomarkers, and mAbs - What Does Primary Care Need?
    N Engl J Med. 2024;390:2229-2231.
    >> Share

  2. STEFANSSON H, Walters GB, Sveinbjornsson G, Tragante V, et al
    Homozygosity for R47H in TREM2 and the Risk of Alzheimer's Disease.
    N Engl J Med. 2024;390:2217-2219.
    >> Share

  3. HARDY J
    Protection against Alzheimer's Disease with APOE Christchurch Variant - How?
    N Engl J Med. 2024;390:2212-2213.
    >> Share

  4. QUIROZ YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, et al
    APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.
    N Engl J Med. 2024;390:2156-2164.
    >> Share

    March 2024
  5. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
    Alzheimer's Disease - Managing Stages of Dementia.
    N Engl J Med. 2024;390:e29.
    >> Share

  6. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
    Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening.
    N Engl J Med. 2024;390:e22.
    >> Share

    February 2024
  7. BATEMAN RJ, Smith J, Doody RS
    Gantenerumab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2024;390:867.
    >> Share

  8. WANG Z, Zhao B, Jia J
    Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2024;390:866.
    >> Share

  9. MAYEUX R
    Alzheimer's Disease Biomarkers - Timing Is Everything.
    N Engl J Med. 2024;390:761-763.
    >> Share

  10. JIA J, Ning Y, Chen M, Wang S, et al
    Biomarker Changes during 20 Years Preceding Alzheimer's Disease.
    N Engl J Med. 2024;390:712-722.
    >> Share

    January 2024
  11. REZAI AR, D'Haese PF, Finomore V, Carpenter J, et al
    Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.
    N Engl J Med. 2024;390:55-62.
    >> Share

    November 2023

  12. Alzheimer's Update, Part 2: ITT Episode 21.
    N Engl J Med. 2023;389:e43.
    >> Share

  13. SCHNEIDER LS
    What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.
    N Engl J Med. 2023;389:1918-1920.
    >> Share

  14. BATEMAN RJ, Smith J, Donohue MC, Delmar P, et al
    Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2023;389:1862-1876.
    >> Share


  15. Alzheimer's Update, Part 1: ITT Episode 20.
    N Engl J Med. 2023;389:e33.
    >> Share

    July 2023
  16. SPERLING RA, Donohue MC, Raman R, Rafii MS, et al
    Trial of Solanezumab in Preclinical Alzheimer's Disease.
    N Engl J Med. 2023 Jul 17. doi: 10.1056/NEJMoa2305032.
    >> Share

    April 2023
  17. VAN DYCK CH, Sabbagh M, Cohen S
    Lecanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2023;388:1631-1632.
    >> Share

  18. BRENMAN JE
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1631.
    >> Share

  19. POMARA N, Imbimbo BP
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630-1631.
    >> Share

  20. VALENZUELA MJ, Pascual-Leone A
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share

  21. ZENG BS, Tseng PT, Liang CS
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share

    January 2023
  22. GANDY S, Ehrlich ME
    Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
    N Engl J Med. 2023;388:80-81.
    >> Share

  23. SABBAGH M, van Dyck CH
    Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
    N Engl J Med. 2023 Jan 4:10.1056/NEJMc2215907#sa1. doi: 10.1056/NEJMc2215907.
    >> Share

    November 2022
  24. VAN DYCK CH, Swanson CJ, Aisen P, Bateman RJ, et al
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2022 Nov 29. doi: 10.1056/NEJMoa2212948.
    >> Share

    November 2021
  25. SACHS RE, Bagley N
    Medicare Coverage of Aducanumab - Implications for State Budgets.
    N Engl J Med. 2021;385:2019-2021.
    >> Share

  26. ROBINSON JC
    Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    N Engl J Med. 2021;385:2017-2019.
    >> Share

    August 2021
  27. ALEXANDER GC, Knopman DS, Emerson SS, Ovbiagele B, et al
    Revisiting FDA Approval of Aducanumab.
    N Engl J Med. 2021;385:769-771.
    >> Share

  28. MINTUN MA, Wessels AM, Sims JR
    Donanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2021;385:667.
    >> Share

  29. ESPAY AJ
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021;385:666-667.
    >> Share

    July 2021
  30. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    >> Share

  31. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    >> Share

    May 2021
  32. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    >> Share

    March 2021
  33. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    >> Share

    October 2020
  34. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016